BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

...board. Goldsmith was a venture partner at Deerfield Management and served as interim CEO of Civetta Therapeutics LLC...
BioCentury | Dec 5, 2019
Emerging Company Profile

Deerfield propels Civetta with $53M series A

...Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular...
...plus royalties. Celgene Corp. is now a unit of Bristol-Myers Squibb Co. (NYSE:BMY). COMPANY PROFILE Civetta Therapeutics LLC...
Items per page:
1 - 2 of 2
BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

...board. Goldsmith was a venture partner at Deerfield Management and served as interim CEO of Civetta Therapeutics LLC...
BioCentury | Dec 5, 2019
Emerging Company Profile

Deerfield propels Civetta with $53M series A

...Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular...
...plus royalties. Celgene Corp. is now a unit of Bristol-Myers Squibb Co. (NYSE:BMY). COMPANY PROFILE Civetta Therapeutics LLC...
Items per page:
1 - 2 of 2